Alberto LleÃ³

List of Publications by Year
in descending order

279	20,974	23544 58	13365 130
papers	citations	h-index	g-index

306	306	306	22627
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Stateâ€ofâ€theâ€art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 159-177.	0.4	33
2	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2022, 60, 207-219.	1.4	44
3	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	1
4	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
5	The AÎ²1â€“42/AÎ²1â€“40 ratio in CSF is more strongly associated to tau markers and clinical progression than AÎ²1â€“42 alone. Alzheimer's Research and Therapy, 2022, 14, 20.	3.0	18
6	Cortical microstructure in primary progressive aphasia: a multicenter study. Alzheimer's Research and Therapy, 2022, 14, 27.	3.0	10
7	Neuropsychological deficits in patients with cognitive complaints after COVIDâ€19. Brain and Behavior, 2022, 12, e2508.	1.0	64
8	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	1.4	7
9	New developments of biofluidâ€based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 2292-2307.	0.4	14
10	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 27.	4.4	30
11	Genome-Wide Association Study of Alzheimerâ€™s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimerâ€™s Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	1.7	20
12	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration, 2022, 17, 29.	4.4	7
13	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
14	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
15	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
16	Importance of cerebrospinal fluid storage conditions for the Alzheimerâ€™s disease diagnostics on an automated platform. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1058-1063.	1.4	4
17	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	2.8	18
18	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA Network Open, 2022, 5, e2212910.	2.8	47

#	Article	IF	Citations
19	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	1.1	9
20	Establishing In-House Cutoffs of CSF Alzheimerâ€™s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. International Journal of Molecular Sciences, 2022, 23, 6891.	1.8	13
21	Myelin loss in C9orf72 hexanucleotide expansion carriers. Journal of Neuroscience Research, 2022, 100, 1862-1875.	1.3	4
22	Serum neurofilament light chain predicts long-term prognosis in Guillain-BarrÃ© syndrome patients. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 70-77.	0.9	40
23	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	1.5	8
24	Biphasic cortical macroâ€•and microstructural changes in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 618-628.	0.4	27
25	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. Alzheimer's and Dementia, 2021, 17, 605-617.	0.4	17
26	White Matter Hyperintensities Are No Major Confounder for Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	1.2	5
27	Biomarker counseling, disclosure of diagnosis and followâ€up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	1.3	19
28	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. Aphasiology, 2021, 35, 240-266.	1.4	7
29	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
30	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.4	34
31	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
32	Race and Alzheimer Disease Biomarkers. Neurology: Genetics, 2021, 7, e574.	0.9	6
33	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	2.8	12
34	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiology of Aging, 2021, 103, 158.e1-158.e5.	1.5	8
35	AMYQ: An index to standardize quantitative amyloid load across PET tracers. Alzheimer's and Dementia, 2021, 17, 1499-1508.	0.4	11
36	Biomarkers in neurological disorders: a fast-growing market. Brain Communications, 2021, 3, fcab086.	1.5	7

#	Article	IF	Citations
37	Different Inflammatory Signatures in Alzheimerâ€™s Disease and Frontotemporal Dementia Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2021, 81, 629-640.	1.2	18
38	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.4	23
39	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
40	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	0.9	30
41	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. Alzheimer's Research and Therapy, 2021, 13, 119.	3.0	6
42	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
43	Plasma Proteomic Biomarkers Relating to Alzheimerâ€™s Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	1.7	16
44	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimerâ€™s disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	5.8	33
45	CSF Proteomic Alzheimerâ€™s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	1.7	9
46	Association of Apolipoprotein E Ã›4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurology, 2021, 78, 937.	4.5	32
47	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. Annals of Neurology, 2021, 90, 407-416.	2.8	7
48	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurology, The, 2021, 20, 605-614.	4.9	29
49	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimerâ€™s disease. Translational Neurodegeneration, 2021, 10, 37.	3.6	8
50	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimerâ€™s disease, but not in cerebral amyloid angiopathy. Alzheimer's Research and Therapy, 2021, 13, 160.	3.0	5
51	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.5	84
52	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	1.4	7
53	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Frontiers in Neurology, 2021, 12, 750543.	1.1	6
54	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, .	0.4	4

#	Article	IF	Citations
55	Lateâ€onset epileptic seizures in adults with Down syndrome are linked to Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
56	Comparison of automated CLEIA and manual ELISA immunoassays for CSF AD biomarkers: The FundaciÃ³ ACE Biomarker Research Program (FACEBREP). Alzheimer's and Dementia, 2021, 17, .	0.4	0
57	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Translational Neurodegeneration, 2021, 10, 50.	3.6	32
58	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
59	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7
60	Calsyntenināŧ1 is a cerebrospinal fluid marker of frontotemporal dementiaâ€related synapse degeneration. Alzheimer's and Dementia, 2021, 17, .	0.4	1
61	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
62	Neuropsychological correlates of plasma NfL in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
63	Alzheimer's disease clinical onset and age at death in people with Down syndrome: A systematic review and populationâ€based study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
64	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
65	Transcriptome-wide characterization of the frontal cortex in FTLD.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e049569.	0.4	0
66	Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055982.	0.4	1
67	Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimerâ€™s disease: Where do we stand?. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 99-113.	2.7	24
68	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	1.5	35
69	Cerebrospinal fluid A beta 1â€“40 peptides increase in Alzheimerâ€™s disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	3.0	33
70	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	54
71	Genome-wide association study of Alzheimerâ€™s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	2.4	42
72	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12052.	1.2	7

#	Article	IF	Citations
73	Dementia and epilepsy. Neurology, 2020, 95, 1074-1075.	1.5	6
74	Cortical microstructure in the amyotrophic lateral sclerosisâ€“frontotemporal dementia continuum. Neurology, 2020, 95, e2565-e2576.	1.5	19
75	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
76	Evaluation of biochemical and hematological parameters in adults with Down syndrome. Scientific Reports, 2020, 10, 13755.	1.6	4
77	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimerâ€™s disease-related inhibitory circuit dysfunction in adults with Down syndrome. Molecular Neurodegeneration, 2020, 15, 46.	4.4	21
78	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.4	1
79	AmyQ: An index to accurately measure cerebral amyloid load. Alzheimer's and Dementia, 2020, 16, e039735.	0.4	0
80	Oligodendroglial alterations in FTD caused by C9orf72 expansion. Alzheimer's and Dementia, 2020, 16, e040196.	0.4	0
81	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. Alzheimer's and Dementia, 2020, 16, e041255.	0.4	0
82	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. Alzheimer's and Dementia, 2020, 16, e041500.	0.4	0
83	Quantifying the synaptic vesicleâ€associated protein, VAMP2, to verify changes in cerebrospinal fluid in preclinical stages of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042717.	0.4	0
84	Transcriptome characterization of the motor cortex suggests microglialâ€related key events due to TDPâ€43 aberrant inclusions. Alzheimer's and Dementia, 2020, 16, e042953.	0.4	0
85	1 Hâ€MRS signature in Alzheimer disease in Down syndrome. Alzheimer's and Dementia, 2020, 16, e043346.	0.4	0
86	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. Alzheimer's and Dementia, 2020, 16, e043491.	0.4	0
87	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. Alzheimer's and Dementia, 2020, 16, e044772.	0.4	0
88	Which preâ€analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. Alzheimer's and Dementia, 2020, 16, e045060.	0.4	0
89	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045268.	0.4	0
90	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.4	1

#	Article	IF	Citations
91	Bloodâ€based detection of earlyâ€stage Alzheimer using multiomics and machine learning. Alzheimer's and Dementia, 2020, 16, e047334.	0.4	0
92	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimerâ€™s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
93	APOE Îµ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 65.	3.0	28
94	Annexin A5 prevents amyloid-Î²-induced toxicity in choroid plexus: implication for Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 9391.	1.6	18
95	Active bilingualism delays the onset of mild cognitive impairment. Neuropsychologia, 2020, 146, 107528.	0.7	24
96	The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy. Clinical Nuclear Medicine, 2020, 45, e239-e240.	0.7	1
97	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Scientific Reports, 2020, 10, 4308.	1.6	26
98	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet, The, 2020, 395, 1988-1997.	6.3	164
99	Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. BMJ Open Diabetes Research and Care, 2020, 8, e001516.	1.2	7
100	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 1585-1595.	1.2	25
101	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology, 2020, 94, e2026-e2036.	1.5	42
102	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
103	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. Cells, 2020, 9, 1252.	1.8	8
104	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1535-1538.	1.4	5
105	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	5.8	170
106	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimerâ€™s disease pathogenesis. Nature Neuroscience, 2019, 22, 1258-1268.	7.1	48
107	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. Developmental Neurobiology, 2019, 79, 716-737.	1.5	30
108	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nature Communications, 2019, 10, 4766.	5.8	73

#	Article	IF	Citations
109	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 597-609.	1.8	44
110	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Annals of Clinical and Translational Neurology, 2019, 6, 1815-1824.	1.7	104
111	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
112	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-Î² positivity. Cortex, 2019, 121, 117-124.	1.1	12
113	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. Clinica Chimica Acta, 2019, 491, 81-84.	0.5	18
114	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 7803.	1.6	33
115	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
116	GBA and APOE Îµ4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Scientific Reports, 2019, 9, 7013.	1.6	53
117	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.4	134
118	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain, 2019, 142, 1121-1133.	3.7	45
119	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 26.	3.0	56
120	Nanoscale structure of amyloid-Î² plaques in Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 5181.	1.6	52
121	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
122	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.4	82
123	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. Sleep, 2019, 42, .	0.6	30
124	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
125	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
126	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.4	0

#	Article	IF	Citations
127	ICâ€Pâ€148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P119.	0.4	0
128	O2â€09â€01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P558.	0.4	0
129	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70
130	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	1.7	13
131	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	2.1	11
132	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	1.5	21
133	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Clinica Chimica Acta, 2019, 490, 98-101.	0.5	17
134	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Molecular and Cellular Proteomics, 2019, 18, 546-560.	2.5	115
135	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
136	Elevated YKL-40 and low sAPPÎ²:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 180-186.	0.9	17
137	Challenges associated with biomarkerâ€based classification systems for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 346-357.	1.2	37
138	El Alzheimer, la enfermedad ignorada. Medicina ClÃ¬nica, 2018, 150, 432-433.	0.3	3
139	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Neurobiology of Aging, 2018, 64, 58-67.	1.5	8
140	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
141	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
142	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	1.5	19
143	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurology, 2018, 75, 738.	4.5	54
144	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.4	122

#	Article	IF	Citations
145	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
146	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 162-168.	0.9	44
147	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
148	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
149	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to earlyâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 99-111.	1.2	9
150	P3â€233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.4	0
151	P4â€076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P1463.	0.4	0
152	Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. Journal of Clinical Sleep Medicine, 2018, 14, 1725-1733.	1.4	56
153	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.4	0
154	P2â€262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.4	0
155	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.4	0
156	O5â€04â€01: A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	0.4	0
157	P1â€277: CORRELATION BETWEEN INNOTESTÂ® AND THE FULLY AUTOMATED LUMIPULSEÂ® G PLATFORM FOR THE ANALYSIS OF Î²â€AMYLOID 1â€42 AND TOTAL TAU. Alzheimer's and Dementia, 2018, 14, P388.	0.4	1
158	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	1.7	28
159	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.5	59
160	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
161	P1â€293: IDENTIFICATION OF EXOSOMAL MICRORNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P398.	0.4	0
162	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12

#	Article	IF	Citations
163	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of AÎ² species. NeuroImage: Clinical, 2018, 20, 603-610.	1.4	11
164	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	4.9	140
165	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	3.0	62
166	Alzheimer's disease: An ignored condition. Medicina ClÃnica (English Edition), 2018, 150, 432-433.	0.1	2
167	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Journal of Alzheimer's Disease, 2018, 64, 505-513.	1.2	16
168	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	1.5	15
169	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	0.7	4
170	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Oncotarget, 2018, 9, 34691-34698.	0.8	57
171	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	1.2	5
172	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimerâ€™s Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
173	MicroRNA Profile in Patients with Alzheimerâ€™s Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. Journal of Alzheimer's Disease, 2017, 57, 483-491.	1.2	126
174	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1251-1260.	0.4	47
175	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimerâ€™s disease. Acta Neuropathologica, 2017, 134, 475-487.	3.9	53
176	Regional Overlap of Pathologies in Lewy Body Disorders. Journal of Neuropathology and Experimental Neurology, 2017, 76, 216-224.	0.9	45
177	Diagnostic and Prognostic Value ofÂtheÂCombination of Two Measures ofÂVerbal Memory in Mild Cognitive Impairment dueÂto Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 909-918.	1.2	28
178	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. Scientific Reports, 2017, 7, 2477.	1.6	28
179	CSF sAPPÎ², YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 2017, 89, 178-188.	1.5	100
180	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197

#	Article	IF	Citations
181	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
182	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87
183	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. Neurobiology of Aging, 2017, 53, 192.e1-192.e4.	1.5	24
184	[O1â€“06â€“02]: BIPHASIC MODEL IN PRECLINICAL ALZHEIMER's DISEASE: AV45 PET, CSF TAU AND CORTICAL THICKNESS. Alzheimer's and Dementia, 2017, 13, P201.	0.4	0
185	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	2.8	51
186	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
187	[P1â€“366]: WEIGHT LOSS MIGHT BE A NONâ€COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P399.	0.4	0
188	[P3â€“274]: STRUCTURAL CORRELATES OF ALZHEIMER's DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY. Alzheimer's and Dementia, 2017, 13, P1048.	0.4	0
189	The pitfalls of biomarkerâ€based classification schemes. Alzheimer's and Dementia, 2017, 13, 1072-1074.	0.4	5
190	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimerâ€™s disease and other tauopathies. Journal of Neuroinflammation, 2017, 14, 118.	3.1	99
191	CSF microRNA Profiling in Alzheimerâ€™s Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	1.9	45
192	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
193	Longitudinal brain structural changes in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 499-509.	0.4	65
194	[P1â€“238]: THE SAPPÎ²/YKLâ€40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P335.	0.4	0
195	[P1â€“289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOIDâ€PET) IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.4	0
196	[P2â€“259]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR ADâ€RELATED SYNAPSE LOSS. Alzheimer's and Dementia, 2017, 13, P712.	0.4	0
197	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer's and Dementia, 2017, 13, P924.	0.4	3
198	Synaptic phosphorylated Î±-synuclein in dementia with Lewy bodies. Brain, 2017, 140, 3204-3214.	3.7	90

#	Article	IF	Citations
199	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Oncotarget, 2017, 8, 104706-104716.	0.8	51
200	Cerebrospinal Fluid Anti-Amyloid-Î² Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2016, 50, 1-7.	1.2	43
201	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. Journal of Alzheimer's Disease, 2016, 50, 539-546.	1.2	38
202	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. Neurobiology of Aging, 2016, 46, 236.e1-236.e6.	1.5	34
203	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392
204	Kidins220 Correlates with Tau inÂAlzheimerâ€™s Disease Brain andÂCerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 55, 1327-1333.	1.2	7
205	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease in Subjects with Down Syndrome. Journal of Alzheimer's Disease, 2016, 55, 1489-1496.	1.2	14
206	P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimerâ€™s Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.4	0
207	O5â€02â€04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMERâ€™S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2016, 12, P380.	0.4	4
208	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0
209	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE. , 2016, 12, P388-P388.		0
210	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-Î² in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	3.7	107
211	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 66.	4.4	9
212	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. Frontiers of Neurology and Neuroscience, 2016, 39, 117-123.	3.0	8
213	Non-Fibrillar Oligomeric Amyloid-Î² within Synapses. Journal of Alzheimer's Disease, 2016, 53, 787-800.	1.2	65
214	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321.		0
215	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid AÎ²42 Levels in Cognitively Normal Elderly. Sleep, 2016, 39, 2041-2048.	0.6	140
216	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 175-180.	1.1	13

#	Article	IF	Citations
217	Assessing the role of TUBA4A gene in frontotemporal degeneration. Neurobiology of Aging, 2016, 38, 215.e13-215.e14.	1.5	9
218	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
219	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.5	54
220	Informantsâ€™ Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimerâ€™s Disease from NormalÂAging. Journal of Alzheimer's Disease, 2015, 48, S87-S98.	1.2	50
221	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. Alzheimer Disease and Associated Disorders, 2015, 29, 353-356.	0.6	8
222	P1-121: Comparison of different ÃŸ-amyloid isoforms in CSF to detect amyloid pathology in cognitively normal subjects and patients with dementia. , 2015, 11, P387-P387.		0
223	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
224	Effect of <scp>REST</scp> on brain metabolism in the Alzheimer disease continuum. Annals of Neurology, 2015, 78, 661-662.	2.8	2
225	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
226	APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget, 2015, 6, 26663-26674.	0.8	92
227	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
228	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the diseaseâ€. Human Molecular Genetics, 2015, 24, 2023-2034.	1.4	45
229	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 710-717.	2.4	39
230	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
231	Analysis of theCHCHD10gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	3.7	56
232	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology, 2015, 85, 626-633.	1.5	131
233	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	1.5	34
234	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2018-2023.	1.5	75

#	Article	IF	Citations
235	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
236	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
237	PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5.	13.7	58
238	Qualitative changes in human Î³-secretase underlie familial Alzheimerâ€™s disease. Journal of Experimental Medicine, 2015, 212, 2003-2013.	4.2	134
239	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	4.9	144
240	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.4	56
241	P3-230: CSF Î²-AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P715-P715.		0
242	IC-P-217: CSF Î²-AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P117-P117.		0
243	Relationship Between Î²-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 157-167.	1.2	106
244	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	5.8	600
245	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	1.5	92
246	Acetylcholinesterase Modulates Presenilin-1 Levels and Î³-Secretase Activity. Journal of Alzheimer's Disease, 2014, 41, 911-924.	1.2	22
247	Autosomalâ€dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter AÎ² production. Journal of Neurochemistry, 2014, 128, 330-339.	2.1	33
248	Cerebrospinal fluid Î²â€amyloid and phosphoâ€tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Annals of Neurology, 2014, 76, 223-230.	2.8	110
249	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 684-691.	0.9	55
250	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	1.5	34
251	Amyloid imaging in depression: a predictor of Alzheimerâ€™s disease?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 711-713.	3.3	1
252	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302

#	Article	IF	Citations
253	Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. Neurobiology of Aging, 2014, 35, 1526-1536.	1.5	9
254	Posttranslational Nitro-Glycative Modifications of Albumin in Alzheimer's Disease: Implications in Cytotoxicity and Amyloid-Î² Peptide Aggregation. Journal of Alzheimer's Disease, 2014, 40, 643-657.	1.2	41
255	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726.	1.2	53
256	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME. , 2014, 10, P882-P882.		2
257	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
258	MAPT H1 haplotype is associated with enhanced Î±-synuclein deposition in dementia with Lewy bodies. Neurobiology of Aging, 2013, 34, 936-942.	1.5	45
259	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathologica, 2013, 125, 201-213.	3.9	103
260	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
261	Confluence of Î±-Synuclein, Tau, and Î²-Amyloid Pathologies in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1203-1212.	0.9	138
262	Tau Enhances Î±-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy. PLoS ONE, 2011, 6, e26609.	1.1	115
263	γ-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2011, 11, 1513-1527.	1.0	43
264	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.9	125
265	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. Journal of Neuropathology and Experimental Neurology, 2010, 69, 53-59.	0.9	52
266	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of Aging, 2010, 31, 725-731.	1.5	196
267	Mild cholesterol depletion reduces amyloidâ€Î²2 production by impairing APP trafficking to the cell surface. Journal of Neurochemistry, 2009, 110, 220-230.	2.1	60
268	Early-Onset Familial Lewy Body Dementia With Extensive Tauopathy: A Clinical, Genetic, and Neuropathological Study. Journal of Neuropathology and Experimental Neurology, 2009, 68, 73-82.	0.9	33
269	Homocysteine and Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2008, 26, 506-512.	0.7	41
270	Activity of γ -Secretase on Substrates Other than APP. Current Topics in Medicinal Chemistry, 2008, 8, 9-16.	1.0	67

#	Article	IF	Citations
271	Current Therapeutic Options for Alzheimers Disease. Current Genomics, 2007, 8, 550-558.	0.7	63
272	Familial Alzheimer's Disease Presenilin 1 Mutations Cause Alterations in the Conformation of Presenilin and Interactions with Amyloid Precursor Protein. Journal of Neuroscience, 2005, 25, 3009-3017.	1.7	139
273	Low Density Lipoprotein Receptor-related Protein (LRP) Interacts with Presenilin 1 and Is a Competitive Substrate of the Amyloid Precursor Protein (APP) for Î³-Secretase. Journal of Biological Chemistry, 2005, 280, 27303-27309.	1.6	57
274	Nonsteroidal anti-inflammatory drugs lower AÎ²42 and change presenilin 1 conformation. Nature Medicine, 2004, 10, 1065-1066.	15.2	206
275	Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated With PS-1 Mutations. American Journal of Geriatric Psychiatry, 2004, 12, 146-156.	0.6	73
276	Notch1 Competes with the Amyloid Precursor Protein for Î³-Secretase and Down-regulates Presenilin-1 Gene Expression. Journal of Biological Chemistry, 2003, 278, 47370-47375.	1.6	45
277	Frequency of Mutations in the Presenilin and Amyloid Precursor Protein Genes in Early-Onset Alzheimer Disease in Spain. Archives of Neurology, 2002, 59, 1759.	4.9	103
278	Uncommon polymorphism in the presenilin genes in human familial Alzheimer's disease: not to be mistaken with a pathogenic mutation. Neuroscience Letters, 2002, 318, 166-168.	1.0	15
279	Cerebral perfusion and haemodynamics measured by SPET in symptom-free patients with transient ischaemic attack: clinical implications. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1828-1835.	3.3	11